Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Robin Harrelson"'
5
The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Autor: Kristin Stadelman, Dmitriy Berenzon, Scott Isom, Sarah Dralle, Bayard L. Powell, Robin Harrelson, Timothy S. Pardee, Susan Lyerly, Leslie R. Ellis, David D. Hurd, Megan Manuel
Publikováno v: Blood. 124:3744-3744
Background: CPI-613 is a first in class agent that targets mitochondrial metabolism through inhibition of pyruvate dehydrogenase and a-ketogluterate dehydrogenase. In a single agent phase I study CPI-613 was found to be well tolerated and several pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24a51d7332d8b03b88a58d1412c0a602
https://doi.org/10.1182/blood.v124.21.3744.3744
Zobrazit plný text záznamu
8
A phase I study of the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies
Autor: Susan Lyerly, Timothy S. Pardee, Denise Levitan, Scott Isom, David D. Hurd, Megan Manuel, Bayard L. Powell, Robin Harrelson, Leslie R. Ellis, Sarah Dralle
Publikováno v: Journal of Clinical Oncology. 31:2516-2516
2516^ Background: Altered metabolism is a hallmark of cancer, including hematologic malignancies. This altered metabolism is a possible therapeutic target. The lipoate derivative CPI-613 is a first in class agent that targets pyruvate dehydrogenase c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ee69ba035ce0a65ac7d26040d067933
https://doi.org/10.1200/jco.2013.31.15_suppl.2516
Zobrazit plný text záznamu
9
Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies
Autor: Laura M DeFord-Watts, David D. Hurd, Bayard L. Powell, Timothy S. Pardee, Denise Levitan, Megan Manuel, Robin Harrelson, Erica Peronto, Susan Lyerly, Steven J. Kridel
Publikováno v: Journal of Clinical Oncology. 30:6524-6524
6524^ Background: Altered metabolism is a hallmark of cancer, including hematologic malignancies. Most tumor cells use glycolysis even under aerobic conditions (the Warburg effect). This altered metabolism is a possible therapeutic target. The novel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::307f1b81adc27ed963a47d5106c005ac
https://doi.org/10.1200/jco.2012.30.15_suppl.6524
Zobrazit plný text záznamu
10
High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial
Autor: Claire Kimbrough, Megan Skiles, Ralph B. D'Agostino, Megan Manuel, David D. Hurd, Bayard L. Powell, Susan Lyerly, Denise Levitan, Robin Harrelson, Leslie R. Ellis
Publikováno v: Blood. 112:1936-1936
High dose cytarabine (HiDAC) is the most effective single agent studied to date for the treatment of acute myeloid leukemia (AML); clofarabine (CLOF) is also an active single agent in AML. Preclinical data suggest synergy between cytarabine and clofa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e44af211a477c6f5c80605ccf0addef3
https://doi.org/10.1182/blood.v112.11.1936.1936
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje